指南与共识妇科肿瘤

人乳头瘤病毒疫苗接种:欧洲妇科肿瘤学会与欧洲阴道镜联盟的立场文件

Human papillomavirus vaccination: The ESGO-EFC position paper of the European society of Gynaecologic Oncology and the European Federation for colposcopy.
指南 / 共识 · Eur J Cancer · 2019-06-01

该立场文件由欧洲妇科肿瘤学会(ESGO)与欧洲阴道镜联盟(EFC)制定,汇总HPV疫苗在预防感染及相关癌前病变和浸润性宫颈癌中的有效性数据,推荐为儿童和青少年实施性别中立疫苗接种并补种年轻成人,指出疫苗联合HPV筛查是预防宫颈癌最有效策略。

要点

  • ESGO与EFC强烈支持为儿童和年轻青少年实施性别中立疫苗接种,并对年轻成人补种。
  • 15岁以下接种两剂(间隔6-12个月)即可,15岁及以上推荐标准三剂方案。
  • 疫苗联合HPV检测筛查是预防宫颈癌最有效方法,接种人群可延长筛查间隔。

核心结论

  • ESGO与EFC强烈支持为儿童和年轻青少年实施性别中立疫苗接种项目,并为年轻成人提供补种项目。

研究设计与样本

  • 由欧洲妇科肿瘤学会(ESGO)与欧洲阴道镜联盟(EFC)制定的立场文件。

主要发现

  • HPV疫苗自2006年起在欧洲上市,在预防疫苗型别所致感染和疾病方面高度有效。
  • 对宫颈、外阴阴道及肛门癌前病变和浸润性宫颈癌已有临床有效性数据。
  • 早期接种且覆盖率超过70%时疾病减少效果最佳。
  • 性别中立接种为所有男性提供直接保护并提高覆盖率,良好覆盖率可产生对未接种男女的群体保护。
  • 基于学校的项目似乎最有效;15岁以下两剂(间隔6-12个月)足够,15岁及以上推荐标准三剂方案。

关键数值与推荐

  • 疾病减少在早期接种且覆盖率超过70%时最佳。
  • 15岁以下:两剂,间隔6-12个月。
  • 15岁及以上:推荐标准三剂方案。
  • 广泛补种项目可提高年轻成人男女的接种有效性。
  • HPV疫苗联合HPV检测筛查是预防宫颈癌最有效方法,接种人群筛查间隔可延长。

临床怎么用

  • ESGO与EFC强烈支持为儿童和年轻青少年实施性别中立疫苗接种项目,并为年轻成人提供补种项目。

局限性

  • 疫苗接种的上限年龄仍待评估,因国家而异并取决于成本效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Vaccines against human papillomavirus (HPV) are available in Europe since 2006. They have been highly effective in preventing infection and disease caused by the vaccine types. Clinical efficacy data are available for cervical, vulvovaginal and anal precancer and invasive cervical cancer. Disease reduction is best with early vaccination and a coverage of more than 70%. Gender-neutral vaccination provides direct protection for all men and improves the coverage. A good coverage is followed by herd protection of the unvaccinated men and women. School-based programs appear to be most effective; under the age of 15 years, two doses with an interval of 6-12 months are sufficient. From the age of 15 years, the standard regimen with three doses is recommended. A broad catch-up program for young adult women and men improves the effectiveness. The vaccines are also effective in sexually active women and men with previous but cleared infections. Vaccination in addition to local treatment of HPV-related disease appears to reduce recurrent or subsequent HPV-related disease. Combination of HPV vaccination and screening with HPV testing is the most effective approach to prevention of cervical cancer. The screening intervals may increase in the vaccinated cohorts. The upper age limit for vaccination remains to be evaluated, is country specific and depends on cost-effectiveness. The European Society of Gynaecologic Oncology and the European Federation for Colposcopy strongly support gender-neutral vaccination programs for children and young adolescents, with a catch-up program for young adults.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Joura EA, Kyrgiou M, Bosch FX, et al. Human papillomavirus vaccination: The ESGO-EFC position paper of the European society of Gynaecologic Oncology and the European Federation for colposcopy. Eur J Cancer. 2019. PMID: 31163338. doi:10.1016/j.ejca.2019.04.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。